SPR741   Click here for help

GtoPdb Ligand ID: 13250

Synonyms: NAB741
Compound class: Peptide or derivative
Comment: SPR741 is a cationic peptide derived from polymyxin B. It is a potentiator molecule that acts by increasing the permeability of the outer membrane of Gram-negative bacteria [3]. It was designed to extend the spectrum and enhance the potency of existing antibacterial compounds and for use in combination therapies to treat severe infections caused by Gram-negative bacteria.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(C)C[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N1)NC(=O)[C@@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)C
Isomeric SMILES C[C@H]([C@H]1C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCN)CCN)CC(C)C)CC2=CC=CC=C2)CCN)NC(=O)[C@@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)C)O
InChI InChI=1S/C44H73N13O13/c1-22(2)19-31-40(66)52-27(11-15-45)36(62)51-29(13-17-47)39(65)57-34(23(3)59)43(69)48-18-14-30(53-42(68)33(21-58)56-44(70)35(24(4)60)49-25(5)61)38(64)50-28(12-16-46)37(63)55-32(41(67)54-31)20-26-9-7-6-8-10-26/h6-10,22-24,27-35,58-60H,11-21,45-47H2,1-5H3,(H,48,69)(H,49,61)(H,50,64)(H,51,62)(H,52,66)(H,53,68)(H,54,67)(H,55,63)(H,56,70)(H,57,65)/t23-,24-,27+,28+,29+,30+,31+,32-,33-,34+,35+/m1/s1
InChI Key JBFNEVNUGGFPBQ-DDMCRLCFSA-N
No information available.
Summary of Clinical Use Click here for help
SPR741 has completed Phase 1 trials to evaluate safety and pharmacokinetics in healthy participants (NCT03022175) and in combination with partner antibacterials (NCT03376529). However, Spero Therapeutics discontinued development of SPR741 (as of January 1, 2020) and have focused on progressing upleganan (Spero Therapeutics, Form 10K, 2019)[1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03022175 A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers Phase 1 Interventional Spero Therapeutics
NCT03376529 Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 Phase 1 Interventional Spero Therapeutics